Filing Details
- Accession Number:
- 0001127602-22-014038
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-10 19:45:36
- Reporting Period:
- 2022-05-10
- Accepted Time:
- 2022-05-10 19:45:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 318154 | Amgen Inc | AMGN | Biological Products, (No Disgnostic Substances) (2836) | 953540776 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1365306 | P Jonathan Graham | One Amgen Center Drive Thousand Oaks CA 91320-1799 | Evp, Gen. Counsel & Secy. | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2022-05-10 | 13,500 | $241.81 | 37,333 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- The price reported is an average price. The prices ranged from $241.73 to $241.97 per share. Full information regarding the number of shares purchased at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,074 RSUs which will vest on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 2,211 RSUs which vest in installments of 1,089 on 5/5/2023 and 1,122 on 5/5/2024; 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and one installment of 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- These shares include 835 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Billionaire Hedge Funds
